JAK2 and neoplasm: The resistance mechanisms of ICI are complex and vary from patient to patient, mainly including tumor‐intrinsic and tumor‐extrinsic factors, such as JAK1/JAK2 mutations, STK11/LKB1 alterations, PTEN loss‐mediated PI3K activation, immunosuppressive tumor microenvironment, and gut microbiome imbalance, etc. [27, 28, 29, 30, 31].